

CITATION REPORT

List of articles citing

Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service

DOI: 10.1097/00007691-199408000-00006
Therapeutic Drug Monitoring, 1994, 16, 368-74.

Source: <https://exaly.com/paper-pdf/25633056/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
257	Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. 1994 , 38, 471-3		195
256	Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. 1995 , 25, 277-90		29
255	Antipsychotic drugs. 1995 , 19, 40-60		
254	Anticonvulsant drugs. 1995 , 19, 61-81		
253	The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. 1995 , 68, 385-424		112
252	Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. 1995 , 39, 151-9		107
251	Cytochrome P4502D6 genotype does not determine response to clozapine. 1995 , 39, 417-20		60
250	Overview of the pharmacokinetics of fluvoxamine. 1995 , 29 Suppl 1, 1-9		67
249	Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. 1995 , 29 Suppl 1, 20-5		63
248	Antidepressant toxicity and the need for identification and concentration monitoring in overdose. 1995 , 29, 154-71		37
247	Clozapine. 1995 , 4, 370-400		69
246	Therapeutic Drug Monitoring. 1995 , 4, 432-453		24
245	No Effect on Plasma Carbamazepine Concentration with Concomitant Omeprazole Treatment. 1995 , 9, 180-181		2
244	Fluvoxamine increases the clozapine serum levels significantly. 1996 , 6, 69-71		37
243	Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. 1996 , 40, 671-4		54
242	Clinically significant interactions of psychotropic agents with antipsychotic drugs. 1996 , 15, 333-46		27
241	Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. 1996 , 31, 198-214		236

240	Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. 1996 , 31, 444-69	159
239	Polymorphic Drug Oxidation. 1996 , 5, 200-223	94
238	Antidepressants and the Cytochrome P450 Enzymes. 1996 , 2, 216-218	1
237	Fluvoxamine-clozapine dose-dependent interaction. 1996 , 41, 670-1	16
236	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. 1996 , 51, 73-8	261
235	Clozapine plasma level monitoring: current status. 1996 , 67, 297-311	29
234	Determination of clozapine in serum by radioreceptor assay versus high-performance liquid chromatography: possible detection of hydroxy-metabolites. 1996 , 21, 337-42	6
233	Psychiatry, psychopharmacology and P-450s. 1996 , 11, 97-114	31
232	In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. 1996 , 42, 518-521	29
231	Plasma Antipsychotic Drug Concentrations: Practical Clinical Considerations. 1996 , 9, 130-132	1
230	A naturalistic study of clozapine serum concentrations in psychiatric patients. 1996 , 50, 413-418	2
229	Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development. 1997 , 7, 139-58	63
228	Drug interactions of clinical significance with selective serotonin reuptake inhibitors. 1997 , 17, 390-406	57
227	Will routine therapeutic drug monitoring have a place in clozapine therapy?. 1997 , 32, 93-100	77
226	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. 1997 , 33, 454-71	129
225	Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. 1997 , 72, 835-47	111
224	Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. 1997 , 32, 210-58	543
223	The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. 1997 , 41, 814-26	32

222	Pharmacogenetics of antidepressants: clinical aspects. 1997 , 391, 14-21	66
221	Analysis of clozapine and norclozapine by high-performance liquid chromatography. 1997 , 696, 253-259	17
220	Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. 1997 , 44, 186-9	55
219	The effect of paroxetine on thiothixene pharmacokinetics. 1997 , 22, 221-6	3
218	The Effect of Chronic Fluvoxamine Treatment on Overnight Melatonin Secretion in Medicated Chronic Schizophrenic Patients. 1997 , 12, 21-25	1
217	Clozapine Drug-Drug Interactions: A Review of the Literature. 1997 , 12, 5-20	25
216	Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients. 1997 , 12, 489-495	13
215	Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. 1997 , 62, 279-86	51
214	Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. 1998 , 64, 484-91	60
213	Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. 1998 , 83, 240-5	28
212	Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. 1998 , 19, 123-32	188
211	Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. 1998 , 54, 167-70	49
210	The progress of COST B1--a European collaboration on the study of interindividual differences in drug disposition and action. Organization for European Co-operation in the field of Science and Technical Research. 1998 , 54, 585-7	1
209	A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. 1998 , 54, 639-43	97
208	Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. 1998 , 54, 735-40	35
207	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. 1998 , 358, 592-9	67
206	Whole saliva and plasma levels of clozapine and desmethylclozapine. 1998 , 23, 35-40	14
205	Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. 1998 , 45, 361-8	53

204	Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. 1998 , 22, 325-33	27
203	Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. 1998 , 22, 723-39	68
202	Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. 1998 , 8, 315-20	14
201	Drug-drug interactions in pediatric psychopharmacology. 1998 , 45, 1233-64, x-xi	11
200	Drug Interactions with Antipsychotic Agents. 1998 , 9, 381-401	19
199	Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. 1998 , 34, 497-502	43
198	A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. 1998 , 16, 35-43	14
197	No Effect of Citalopram on Plasma Levels of Clozapine, Risperidone and their Active Metabolites in Patients with Chronic Schizophrenia. 1998 , 16, 393-398	22
196	The clinical use of plasma clozapine levels. 1998 , 32, 567-74	36
195	Management of the adverse effects of clozapine. 1998 , 24, 381-90	191
194	RE: False Memory Syndrome ¶Balancing the evidence for and against. 1998 , 15, 113-113	2
193	False Memory Syndrome. 1998 , 15, 113-113	
192	Fatal pharmacokinetic interaction involving amitriptyline combined with valproate and clozapine. 1998 , 15, 113-114	
191	Pharmacogenetics of the hepatic cytochrome P450 enzyme system: its relevance for prescribing in psychiatry. 1998 , 15, 96-99	
190	RE: Clozapine-fluoxetine and the CYP450 system. 1998 , 15, 112-113	
189	Serum¶inger ved clozapinbehandling (TDM). 1998 , 51, 69-76	
188	Facing the Issue of Drug Interactions in Elderly Depressed Patients. 1998 , 13, 171-177	
187	Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. <i>Journal of Psychopharmacology</i> , 1998 , 12, S89-97	4.6 22

186	The Metabolism of Atypical Antipsychotic Drugs: An Update. 1999 , 11, 145-158	26
185	Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene. 1999 , 4, 30-34, 47-56	14
184	Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. <i>Pharmacopsychiatry</i> , 1999 , 32, 148-53 ²	63
183	A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. 1999 , 48, 669-77	52
182	Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. 1999 , 47, 397-402	32
181	Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. 1999 , 24, 7-16	70
180	Interspecies variability and drug interactions of clozapine metabolism by microsomes. 1999 , 13, 577-81	22
179	Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. 1999 , 65, 369-76	92
178	Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. 1999 , 19, 491-510	31
177	Metabolism and excretion of mood stabilizers and new anticonvulsants. 1999 , 19, 511-32	50
176	Elevated plasma levels of clozapine after concomitant use of fluvoxamine. 1999 , 21, 243-4	24
175	Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. 1999 , 54, 943-6	22
174	Absence of interaction between erythromycin and a single dose of clozapine. 1999 , 55, 221-6	40
173	Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. 1999 , 118, 171-89	46
172	Drug metabolism and atypical antipsychotics. 1999 , 9, 301-9	65
171	Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. 1999 , 9, 453-9	42
170	Pharmacokinetics of haloperidol: an update. 1999 , 37, 435-56	171
169	Clozapine augmentation: safety and efficacy. 2000 , 26, 421-40	55

168	Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. 2000 , 49, 59-63		42
167	Therapeutic drug monitoring of psychotropic medications. 2000 , 49, 303-12		39
166	Pharmacokinetics of selective serotonin reuptake inhibitors. 2000 , 85, 11-28		568
165	Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. 2000 , 152, 80-6		38
164	Ciprofloxacin increases serum clozapine and N-desmethylozapine: a study in patients with schizophrenia. 2000 , 56, 585-9		71
163	Oxidative stress induced by the metabolism of medical and nonmedical drugs. 2000 , 1021-1051		
162	Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. <i>Pharmacopsychiatry</i> , 2000 , 33, 213-7	2	59
161	Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. 2000 , 47, 252-66		83
160	Clinically significant pharmacokinetic interactions between dietary caffeine and medications. 2000 , 39, 127-53		207
159	Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions. 2001 , 24, 947-59		16
158	The dose-concentration-effect relationships: the basis for TDM. A critical appraisal. 2001 , 1220, 117-123		2
157	No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 675-8	3.2	18
156	Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 410-3	3.2	63
155	CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 398-407	1.7	61
154	Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection. 2001 , 755, 349-54		17
153	Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia. 2001 , 57, 705-8		24
152	Therapeutic drug monitoring of psychotropic medications. 2001 , 52, 45-54		4
151	Therapeutic drug monitoring of psychotropic medications. 2001 , 52, 45-54		53

150	When symptoms persist: clozapine augmentation strategies. 2001 , 27, 615-28		100
149	Newer antipsychotics: comparative review of drug interactions. 2001 , 1, 171-82		11
148	Antidepressant Drug Interactions. 2001 , 14, 467-477		2
147	[Atypical antipsychotics in the treatment of bipolar affective disorders]. 2002 , 70, 234-42		2
146	Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 502-6	1.7	55
145	Psychiatric Pharmacogenetics: Prediction of Treatment Outcomes in Schizophrenia. 369-378		1
144	Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. 2002 , 12, 255-60		41
143	Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?. 2002 , 41, 453-70		123
142	Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. 2002 , 10, 280-91		63
141	Clinically significant drug interactions with antidepressants in the elderly. 2002 , 19, 299-320		101
140	Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. 2002 , 26, 699-703		23
139	. 2002 ,		24
138	Bacterial pneumonia can increase serum concentration of clozapine. 2002 , 58, 321-2		46
137	Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. 2002 , 58, 587-91		16
136	Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. 2002 , 43 Suppl 2, 37-44		91
135	Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). 2002 , 71, 141-52		66
134	Metabolic drug interactions with new psychotropic agents. 2003 , 17, 517-38		138
133	What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. 2003 , 42, 607-18		143

132	Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. 2003 , 48, 411-4		36
131	The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. 2003 , 13, 169-72		124
130	The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. 2004 , 44, 785-92		25
129	Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. 2004 , 44, 1083-105		148
128	Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. 2004 , 57, 487-94		64
127	Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. 2004 , 59, 879-82		86
126	Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. 2004 , 14, 39-44		34
125	Therapeutic drug monitoring of antidepressant and antipsychotic drugs. 2004 , 255-271		1
124	Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. 2004 , 43, 33-56		26
123	Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 70-8	1.7	170
122	A review of clozapine safety. 2005 , 4, 731-44		75
121	Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients. 2005 , 51, 173-6		8
120	Augmentation strategies in clozapine-resistant schizophrenia. 2005 , 19, 843-72		69
119	An overview of psychotropic drug-drug interactions. 2005 , 46, 464-94		98
118	Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. 2005 , 52, 497-501		13
117	Interactions between antiepileptic and antipsychotic drugs. 2006 , 29, 95-118		55
116	Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 599-602	3.2	37
115	Susceptibility genes for the side effect of antipsychotics on body weight and obesity. 2006 , 7, 1681-95		28

114	Interaktionen zwischen Antiepileptika und Psychopharmaka. 2006 , 19, 95-108	0
113	Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response. 2006 , 2, 77-94	1
112	CYP-mediated clozapine interactions: how predictable are they?. 2007 , 8, 307-13	45
111	Clozapine. 2007 , 1-6	1
110	Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. 2007 , 30, 107-13	17
109	Preventing drug interactions with antidepressants in the elderly. 2007 , 3, 231-243	
108	Clozapine case series. 2007 , 48, 170-5	29
107	Abordaje farmacológico de las esquizofrenias resistentes a clozapina. A propósito de un caso. 2007 , 14, 1-6	
106	Metabolic differences between Asian and Caucasian patients on clozapine treatment. 2007 , 22, 217-22	21
105	Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. 2007 , 82, 606-9	73
104	Metabolic drug interactions with newer antipsychotics: a comparative review. 2007 , 100, 4-22	198
103	Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. 2008 , 64, 159-66	45
102	Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. 2008 , 30, 1206-27	269
101	Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. 2008 , 36, 2547-55	25
100	Personalized Medicine: Pharmacogenetics in Psychiatry. 2008 , 6, 1-11	3
99	Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. 2008 , 9, 410-8	154
98	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. 2009 , 16, 4066-218	86
97	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 319-26	1.7 98

96	Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5Sflanking region. 2010 , 79, 261-9		69
95	Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. 2010 , 42, 268-354		186
94	Augmenting Clozapine Response in Treatment-Resistant Schizophrenia. 2010 , 129-151		4
93	Clozapine-related EEG changes and seizures: dose and plasma-level relationships. <i>Therapeutic Advances in Psychopharmacology</i> , 2011 , 1, 47-66	4.9	80
92	Factors affecting interindividual differences in clozapine response: a review and case report. 2011 , 26, 177-87		20
91	Interactions and monitoring of antipsychotic drugs. <i>Handbook of Experimental Pharmacology</i> , 2012 , 241-65		14
90	Psychotropic drug-drug interactions involving P-glycoprotein. 2012 , 26, 959-73		40
89	Current Antipsychotics. <i>Handbook of Experimental Pharmacology</i> , 2012 ,	3.2	5
88	Sudden death of cardiac origin and psychotropic drugs. 2012 , 3, 76		21
87	Interactions between antiepileptics and second-generation antipsychotics. 2012 , 8, 311-34		45
86	Clinically relevant drug interactions in anxiety disorders. 2012 , 27, 239-53		28
85	Elevated clozapine serum levels in combination with perazine. 2013 , 226, 623-5		9
84	Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?. 2013 , 225, 505-18		63
83	Clinically significant drug interactions with atypical antipsychotics. 2013 , 27, 1021-48		66
82	Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. 2013 , 147, 368-74		29
81	Characterization of human cytochrome P450s involved in the bioactivation of clozapine. 2013 , 41, 651-8		38
80	Therapeutic drug monitoring for tomorrow. 2013 , 69 Suppl 1, 25-32		43
79	Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. 2014 , 16, 409-31		151

78	Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. 2014 , 10, 721-46	70
77	Use of anticonvulsants as prophylaxis for seizures in patients on clozapine. 2014 , 22, 78-83	20
76	Drug interactions affecting clozapine levels. 2015 , 11, 52-65	8
75	A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review. 2015 , 94, e1752	10
74	Seizure associated with clozapine: incidence, etiology, and management. 2015 , 29, 101-11	61
73	The effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. 2016 , 14, 765-71	12
72	[Therapeutic drug monitoring of clozapine]. 2016 ,	
71	Pharmacovigilance in Psychiatry. 2016 ,	4
70	The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. 2016 , 233, 741-50	36
69	Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. 2016 , 12, 407-22	56
68	Monitoring of Plasma Concentrations of Psychotropic Drugs in Pharmacovigilance. 2016 , 95-119	
67	Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. 2016 , 106, 72-86	59
66	Potential Role of Patients CYP3A-Status in Clozapine Pharmacokinetics. 2017 , 20, 529-537	18
65	Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors. 2018 , 122, 388-395	7
64	Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. 2018 , 192, 20-41	80
63	The Integrated Optimization of Safety and DMPK Properties Enabling Preclinical Development: A Case History with S1P1 Agonists. 2018 , 603-630	
62	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. 2019 , 12, 603-621	41
61	Exploring the Prevalence of Clozapine Phenotypic Poor Metabolizers in 4 Asian Samples: They Ranged Between 2% and 13. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 644-648	1.7 18

60	Clozapine Metabolism in East Asians and Caucasians: A Pilot Exploration of the Prevalence of Poor Metabolizers and a Systematic Review. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 135-144	1.7	29
59	Population Pharmacokinetics of Clozapine: A Systematic Review. 2020 , 2020, 9872936		10
58	Therapeutic drug monitoring of antidepressant and antipsychotic drugs. 2020 , 7, 257-275		1
57	Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes. <i>Pharmaceutics</i> , 2020 , 12,	6.4	11
56	Is there a future for pharmacogenetics in the optimal dosing of clozapine?. <i>Pharmacogenomics</i> , 2020 , 21, 369-373	2.6	12
55	Using therapeutic drug monitoring to personalize clozapine dosing in Asians. <i>Asia-Pacific Psychiatry</i> , 2020 , 12, e12384	3.2	4
54	A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. <i>Psychotherapy and Psychosomatics</i> , 2020 , 89, 200-214	9.4	38
53	Possible pharmacogenetic factors in clozapine treatment failure: a case report.. <i>Therapeutic Advances in Psychopharmacology</i> , 2021 , 11, 20451253211030844	4.9	1
52	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 140-147	1.7	6
51	Past, present and future perspectives of therapeutic drug monitoring in India. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14189	2.9	2
50	Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations. <i>Neurology International</i> , 2021 , 13, 445-463	1.2	1
49	Therapeutic Drug Monitoring in Neuropsychiatric Disorders. 2020 , 1-11		1
48	Carbamazepine. <i>Handbook of Experimental Pharmacology</i> , 1999 , 267-317	3.2	0
47	Comments to "interaction between caffeine and clozapine". <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 376-7	1.7	9
46	Dosing of antidepressants--the unknown art. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 435-9	1.7	9
45	Plasma level measurement in a patient with clozapine intoxication. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 86-7	1.7	10
44	Pharmacokinetics of clozapine and risperidone: a review of recent literature. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 177-87	1.7	79
43	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 273-85	1.7	61

42	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 345-55	1.7	59
41	Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 68-9	1.7	33
40	Interaction of sertraline with clozapine. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 119-20	1.7	32
39	Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 2-9	1.7	120
38	Clozapine and fluvoxamine, a curious complexity. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 101-2.7		15
37	Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 311-6	1.7	62
36	Extrapyramidal symptoms after addition of fluvoxamine to clozapine. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 483-4	1.7	22
35	Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 289-91	1.7	25
34	Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 494-9	1.7	49
33	Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 35-42	1.7	58
32	Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 110-2	1.7	20
31	Comments on in vitro and in vivo studies of fluvoxamine-clozapine interaction. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 527-8	1.7	1
30	Dosing strategies of clozapine-fluvoxamine cotreatment. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 626-8	1.7	5
29	Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 200-7	3.2	48
28	Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 254-62	3.2	75
27	Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 56-62	3.2	36
26	Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 219-23	3.2	51
25	Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 628-30	3.2	29

24	Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 87-90	3.2	99
23	Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 166-70	3.2	22
22	Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 341-5	3.2	70
21	Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 580-2	3.2	55
20	Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 143-54	3.2	105
19	Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 409-17	3.2	108
18	Metabolic Models of Cytotoxicity. 1999 , 443-476		1
17	Treating Depression: Potential Drug Interactions. <i>Psychiatric Annals</i> , 1997 , 27, 244-258	0.5	7
16	The Comorbidity of Obsessive-Compulsive Disorder and Schizophrenia. <i>Psychiatric Annals</i> , 1999 , 29, 533-536		2
15	Indicators of response to clozapine treatment. <i>Mental Health Clinician</i> , 2015 , 5, 74-77	1.6	1
14	Clozapine augmentation strategies. <i>Mental Health Clinician</i> , 2019 , 9, 336-348	1.6	8
13	Auftreten von Nebenwirkungen unter Clozapin-Fluvoxamin-Kombination. 2001 , 133-138		
12	Serotonin-selektive Antidepressiva(SSRI, DSA). 2002 , 223-363		
11	Forschungsschwerpunkte der Klinik Therapeutisches Drug Monitoring (TDM) von Neuroleptika. 2003 , 233-238		
10	Interaktionen von Clozapin mit anderen Psychopharmaka. 1997 , 39-57		1
9	Bedeutung des therapeutischen Drug-Monitoring im Rahmen der Rezidivprophylaxe mit Clozapin. 1999 , 79-89		2
8	Complex drug interaction of carbamazepine, fluvoxamine and clozapine in a patient with bipolar depression. <i>Revista De Psiquiatria Clinica</i> , 2019 , 46, 171-171	0.8	
7	Therapeutic Drug Monitoring in Neuropsychiatric Disorders. 2020 , 753-763		

6	Interactions between the cytochrome P450 system and the second-generation antipsychotics. <i>Journal of Psychiatry and Neuroscience</i> , 2003 , 28, 99-112	4.5	92
5	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , 2021 , 55,	2	11
4	The history of clozapine in clinical practice: From its introduction to a guideline proposing personalized titrations. <i>Journal of Psychopharmacology</i> , 2022 , 36, 657-660	4.6	1
3	An international clozapine titration guideline for clozapine: An opportunity for moving forward on personalizing clozapine treatment in India and other countries. <i>Indian Journal of Psychiatry</i> , 2022 , 64, 331	2.2	0
2	Effect of Venlafaxine on CYP1A2-Dependent Pharmacokinetics and Metabolism of Caffeine. 1999 , 39, 252-259		2
1	Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. 2022 ,		0